This menu provides the list of EV proteins identified by high-throughput analyses.
Refresh all contents
Search:
Dataset accession
UniProt accession
UniProt name
Protein name
Gene symbol
Species
Orthologous group
Superdomain:
All
Prokaryote
Eukaryote
Filter datasets:
- "Sample type" indicates the source from which EVs originated (e.g. B cell, serum).
- "Sample status" indicates the condition of the source from which EVs originated (e.g. Normal, miR-146a-treated, Patients of hernia).
By species
Bos taurus
Canis familiaris
Homo sapiens
Mus musculus
Mus musculus, Plasmodium yoelii
Rattus norvegicus
Sus scrofa
In vitro/In vivo
Ex vivo
In vitro
In vivo
By sample type
Amnion epithelial cell
Amniotic fluid
Amniotic fluid stem cell
Aqueous humor of age-related macular degeneration
Ascites
B cell (RN (HLA-DR15))
Blood
Bone marrow aspirate
Bone marrow stromal cell
Bone marrow-derived mesenchymal stem cell (MSC)
Brain
Breast cancer cell (BT549)
Breast cancer cell (HS 578T)
Breast cancer cell (MCF-7)
Breast cancer cell (MCF7)
Breast cancer cell (MDA-MB-231)
Breast cancer cell (MDA-MB-468)
Breast cancer cell (T-47D)
Breast milk
Bronchial epithelial cell (30KT)
Bronchoalveolar lavage fluid
Cardiac fibroblasts
Carotid atherosclerotic plaque
Central nervous system cancer cell (SF268)
Central nervous system cancer cell (SF295)
Central nervous system cancer cell (SF539)
Central nervous system cancer cell (SNB-19)
Central nervous system cancer cell (SNB-75)
Central nervous system cancer cell (U251)
Cerebral cortical neural cells
Cerebrospinal fluid
Cervical cancer (HeLa)
Choriocarcinoma cell (JEG3)
Chronic lymphoid leukemia cell (MEC-1)
Chronic myeloid leukemia (K562)
Colon cancer cell (Colo205)
Colon cancer cell (HCC 2998)
Colon cancer cell (HCT-116)
Colon cancer cell (HCT-15)
Colon cancer cell (HT29)
Colon cancer cell (KM12)
Colon cancer cell (SW480)
Colon cancer cell (SW620)
Colorectal cancer cell (HT29)
Colorectal cancer cell (LIM1215)
Colorectal cancer cell (SW480)
Colorectal cancer cell (SW620)
Colorectal cancer cells (HCT116, DLD1, SW480, SW620)
Dendritic cell
Dermal fibroblast (HDF)
Embryonic kidney cell (293T)
Embryonic kidney cell (HEK293)
Embryonic kidney cell (HEK293T)
Embryonic kidney cells (293T)
Embryonic stem cell derived mesenchymal stem cell
Endothelial cell (HMEC-1)
Endothelial progenitor cell
Epithelial ovarian carcinoma cell (OVCAR3, OVCAR433, OVCAR5 , SKOV3)
Erythrocyte
Expressed prostatic secretions in urine
Extravillous trophoblast cell (HTR8/SVneo)
Fetal bovine serum
Glioblastoma cell (U87)
Hepatic stellate cell
Hepatocellular carcinoma cell (Hep3B)
Hepatocellular carcinoma cell (Huh7)
Hepatocellular carcinoma cell (LM3)
Hepatocyte
Hepatoma cell (Huh-7)
Keratinocyte
Kidney cancer cell (786-O)
Kidney cancer cell (A498)
Kidney cancer cell (ACHN)
Kidney cancer cell (CAKI)
Kidney cancer cell (RXF 393)
Kidney cancer cell (SN12C)
Kidney cancer cell (TK-10)
Kidney cancer cell (UO-31)
Leukemia cell (CCRF-CEM)
Leukemia cell (HL-60)
Leukemia cell (K562)
Leukemia cell (MOLT-4)
Leukemia cell (RPMI-8226)
Leukemia cell (SR)
Leukopak
Lung cancer cell (A549)
Lung cancer cell (HOP-62)
Lung cancer cell (HOP-92)
Lung cancer cell (NCI-H226)
Lung cancer cell (NCI-H23)
Lung cancer cell (NCI-H322M)
Lung cancer cell (NCI-H460)
Lung cancer cell (NCI-H522)
Lung cancer pleural effusion
Lung epithelial cell (E10)
Macrophage
Macrophage (THP1)
Mammary epithelial cell (MCF10A)
Mast cell (MC9)
Melanocyte
Melanoma (B16F10)
Melanoma cell (1205Lu)
Melanoma cell (501mel)
Melanoma cell (A375M)
Melanoma cell (B16-F1)
Melanoma cell (B16-F10)
Melanoma cell (B16-F10, SK-MEL-202, SK-MEL035, SK-MEL-265)
Melanoma cell (B16-OVA)
Melanoma cell (Daju)
Melanoma cell (G1)
Melanoma cell (LOX IMVI)
Melanoma cell (M14)
Melanoma cell (MALME-3M)
Melanoma cell (MDA-MB-435)
Melanoma cell (MNT-1)
Melanoma cell (SK-MEL-2)
Melanoma cell (SK-MEL-28)
Melanoma cell (SK-MEL-5)
Melanoma cell (SKMEL28)
Melanoma cell (UACC-257)
Melanoma cell (UACC-62)
Mesenchymal stem cell
Mesothelioma cell (JO38)
Microglial cell
Middle-ear epithelial cell (HMEEC-1)
Milk
Monocyte (THP-1)
Monocyte-derived macrophage
Monocyte-derived macrophages
Myeloid-derived suppressor cell
Nasal lavage
Neonatal myoblast cell
Neuroblastoma cell (CHLA255)
Neuroblastoma cell (HTLA-230)
Neuroblastoma cell (IGR-N91)
Neuroblastoma cell (IGR-NB8)
Neuroblastoma cell (IMR32)
Neuroblastoma cell (LAN-1)
Neuroblastoma cell (SH-SY5Y)
Neuroblastoma cell (SK-N-SH)
Neuroblastoma cell (SKNBe2c)
Neutrophil
Non small cell lung cancer (A549)
Non small cell lung cancer (HCC827)
Normal B cell (BJAB)
Normal bronchial epithelial cell (HBE4)
Oligodendrocyte
Oral squamous cell carcinoma cell (BHY)
Osteosarcoma cell (MG63)
Osteosarcoma cell (SAOS-2)
Osteosarcoma cell (U2OS)
Ovarian cancer (OVCA429)
Ovarian cancer cell (IGROV1)
Ovarian cancer cell (NCI-ADR-RES)
Ovarian cancer cell (OVCAR-3)
Ovarian cancer cell (OVCAR-4)
Ovarian cancer cell (OVCAR-5)
Ovarian cancer cell (OVCAR-8)
Ovarian cancer cell (SK-OV-3)
Pancreatic ductal adenocarcinoma cell (Pa03C)
Pancreatic ductal adenocarcinoma cell (Pa21C)
Pancreatic ductal adenocarcinoma cell (Pa28C)
Pancreatic ductal epithelial cell (HPNE)
Peritoneal dialysis effluent
Placental mesenchymal stem cell
Placental villous tissue
Plasma
Platelet
Platelet-poor plasma
Primary hepatocyte
Prostate cancer cell (DU145)
Prostate cancer cell (DuCaP)
Prostate cancer cell (LNCaP)
Red blood cell
Retinal pigment epithelial cell (RPE-1)
Seminal plasma
Serum
T cells (ED40515(-))
Thymus
Urinary bladder transitional cell carcinoma (FL3)
Urinary bladder transitional cell carcinoma (SLT4)
Urinary bladder transitional cell carcinoma (T24)
Urine
Uterine flushing fluid
W8B2+ cardiac stem cell
Whole blood
By sample status
-80oC storage
4T1-injected (conventional)
4T1/IL-1β-injected (inflammatory)
4oC storage
ATP-stimulated_ectosome
ATP-stimulated_exosome
Acute pancreatitis
Amyloid-beta42 protofibril-exposed
Androgen-deprived
Bioreactor culture
Breast cancer-bronchiectasis non-tuberculosis Mycobacterium-infected
Bronchiectasis non-tuberculosis Mycobacterium-infected
CD63-CRISPR
CHAPS-treated
Cell-mediated rejection
Centrifugation
Cholera toxin B-bound
Cholera toxin B-depleted
Choline supplemented L-amino acid (CSAA)-fed
Chondroitin sulfate-treated
Cocultured with C. albicans
Colorectal cancer
Colostrum collected within 24 h of calving
Colostrum collected within 48 h of calving
Colostrum collected within 72 h of calving
Constitutive_ectosome
Constitutive_exosome
Control
Control_24 h
Control_48 h
Conventional
Curcumin-treated
Cystinuria patients, molecular weight fractionation
Cystinuria patients, pI fractionation
DTT-treated
Day 17 pregnancy
Day 20 pregnancy
Day 22 pregnancy
Deoxyelephantopin (DET)-treated
Deoxyelephantopin derivative-35 (DETD-35)-treated
Diabetes
Differentiated
Dihydrotestosterone-treated
Docetaxel-resistant
Docetaxel-sensitive
Donor 1 (Exo-Spin)
Donor 1 (SEC fraction 11)
Donor 1 (SEC fraction 7+8)
Donor 1 (SEC fraction 9+10)
Donor 2 (Exo-Spin)
Donor 3 (Exo-Spin)
Donor 3 (SEC fraction 8)
Doxorubicin-treated
Exosome
Exosomes
Experimental cerebral malaria
F3-10K
F5-100K
F5-10K
Flask culture
Freshly isolated
Galactosamine-treated
HIV-1-infected_Exosome
HTLV-1-infected, Tax-negative
Healthy
Helicobacter pylori-infected
High density exosomes
High-grade bladder cancer
High-risk prostate cancer (Gleason score 8-9)
Hypertensive patients under chronic suppression of RAS
Hypoxia
Hypoxic condition
IL3-Lamp2b-transfected
Idiopathic longitudinally extensive transverse myelitis
Influenza A virus-infected
Insulin-induced
Irradiated (6 Gy)
LATS1/2-/-
Lacunar infarction-cognitive decline without recurrent vascular events
Lacunar infarction-no adverse outcome
Lacunar infarction-recurrent vascular events
Low density exosomes
Low-grade prostate cancer patient
Low-risk prostate cancer (Gleason score 6)
Low-sulfated hyaluronic acid-treated
M. tuberculosis-infected
Mature milk
Microvesicle
Microvesicle, Storage day 3
Microvesicles
Multiple myeloma
Multiple sclerosis
Mycobacterium tuberculosis-infected_Orbitrap
Mycobacterium tuberculosis-infected_QSTAR
Nanovesicle, Storage day 21
Nanovesicle, Storage day 3
Nanovesicle, Storage day 42
Neuromyelitis optica
Non-small cell lung cancer patient
Non-sulfated hyaluronic acid-treated
Nontypeable Haemophilus influenzae lysate-treated_24 h
Nontypeable Haemophilus influenzae lysate-treated_48 h
Normal
Normal cow
Normal donors
Normal donors and patients of deep venous thrombosis
Normal rat
Normal_Annexin V-binding EVs
Normal_Orbitrap
Normal_QSTAR
Normal_Ultracentrifugation
Oxidative stress
P. falciparum-infected
PDGF-BB-treated
PEG precipitation
Parkinson's disease patient
Patient of developmental heart defect_exosome
Patient of developmental heart defect_microparticle
Patients of basement membrane nephropathy
Patients of bladder cancer
Patients of carotid atherosclerosis
Patients of colorectal cancer
Patients of external counterpulsation therapy
Plasmodium yoelii-infected
Preeclampsia patients
Preeclampsia_Annexin V-binding EVs
Preeclampsia_Cholera toxin part B-binding EVs
Protein organic solvent precipitation
Radiation
Rat of pulmonary embolism model
ST-eleavated myocardial infarction
Size exclusion chromatography
Staphylococcus aureus-infected
Stimulated by IgG
Stimulated in immobile phase
Stimulated with beta-glucan
Stressed (hypoxia, TNF-慣-induced activation, high glucose and mannose concentrations)
TGF-β-treated
Trauma patients
Tubular injury
Ultra-cushion
Ultracentrifugation
p53 knock-down and EGFR L858R point mutation
pCMV-HA-HBx-transfected
pCMV-HBV1.1(X')-transfected
pCMV-HBV1.1-transfected
pCMV-transfected
Number of molecules in one page:
100
200
All
The downloaded CSV file is not exactly the same as the displayed table. Opening CSV file with Excel can impair its content.
Protein name
UniProt accession
Publication
Orthologous group
Identification count
All / Prokaryote / Eukaryote
Apolipoprotein E (Apo-E)
P02649
The platelet microparticle proteome.
J Proteome Res. 2005 Sep-Oct;4(5):1516-21.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P08226
Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells.
Nat Cell Biol. 2007 Jun;9(6):654-9. Epub 2007 May 7.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Exosomes with immune modulatory features are present in human breast milk.
J Immunol. 2007 Aug 1;179(3):1969-78.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
The proteome of red cell membranes and vesicles during storage in blood bank conditions.
Transfusion. 2008 May;48(5):827-35.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
The proteome of red cell membranes and vesicles during storage in blood bank conditions.
Transfusion. 2008 May;48(5):827-35.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
The proteome of red cell membranes and vesicles during storage in blood bank conditions.
Transfusion. 2008 May;48(5):827-35.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
The proteome of red cell membranes and vesicles during storage in blood bank conditions.
Transfusion. 2008 May;48(5):827-35.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Isolation and identification of potential urinary microparticle biomarkers of bladder cancer.
J Proteome Res. 2008 May;7(5):2088-96. doi: 10.1021/pr700775x. Epub 2008 Mar 29.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic profiling of human plasma exosomes identifies PPARgamma as an exosome-associated protein.
Biochem Biophys Res Commun. 2009 Jan 16;378(3):433-8. doi: 10.1016/j.bbrc.2008.11.050. Epub 2008 Nov 24.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Large-scale proteomics and phosphoproteomics of urinary exosomes.
J Am Soc Nephrol. 2009 Feb;20(2):363-79. doi: 10.1681/ASN.2008040406. Epub 2008 Dec 3.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
Q03247
Anchorage-independent growth of breast carcinoma cells is mediated by serum exosomes.
Exp Cell Res. 2009 Jul 1;315(11):1875-88. doi: 10.1016/j.yexcr.2009.03.010. Epub 2009 Mar 24.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02650
Characterization and comprehensive proteome profiling of exosomes secreted by hepatocytes.
J Proteome Res. 2008 Dec;7(12):5157-66.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures.
Blood. 2009 Jul 16;114(3):723-32. doi: 10.1182/blood-2009-02-205930. Epub 2009 Apr 15.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Profile of exosomes related proteins released by differentiated and undifferentiated human keratinocytes.
J Cell Physiol. 2009 Oct;221(1):221-31. doi: 10.1002/jcp.21847.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Differential stimulation of monocytic cells results in distinct populations of microparticles.
J Thromb Haemost. 2009 Jun;7(6):1019-28. doi: 10.1111/j.1538-7836.2009.03434.x.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Differential stimulation of monocytic cells results in distinct populations of microparticles.
J Thromb Haemost. 2009 Jun;7(6):1019-28. doi: 10.1111/j.1538-7836.2009.03434.x.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomics, metabolomics, and immunomics on microparticles derived from human atherosclerotic plaques.
Circ Cardiovasc Genet. 2009 Aug;2(4):379-88. doi: 10.1161/CIRCGENETICS.108.842849. Epub 2009 May 14.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomics of microparticles after deep venous thrombosis.
Thromb Res. 2010 Jun;125(6):e269-74. doi: 10.1016/j.thromres.2010.01.019. Epub 2010 Feb 13.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
MHC class II-associated proteins in B-cell exosomes and potential functional implications for exosome biogenesis.
Immunol Cell Biol. 2010 Nov-Dec;88(8):851-6. doi: 10.1038/icb.2010.64. Epub 2010 May 11.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P08226
Oligodendrocytes secrete exosomes containing major myelin and stress-protective proteins: Trophic support for axons?
Proteomics Clin Appl. 2007 Nov;1(11):1446-61. doi: 10.1002/prca.200700522. Epub 2007 Oct 16.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Microfiltration isolation of human urinary exosomes for characterization by MS.
Proteomics Clin Appl. 2010 Jan;4(1):84-96. doi: 10.1002/prca.200800093. Epub 2009 Nov 11.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic analysis of urinary exosomes from patients of early IgA nephropathy and thin basement membrane nephropathy.
Proteomics. 2011 Jun;11(12):2459-75. doi: 10.1002/pmic.201000443. Epub 2011 May 18.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Fragment)
E7ERP7
Proteomic analysis of urinary exosomes from patients of early IgA nephropathy and thin basement membrane nephropathy.
Proteomics. 2011 Jun;11(12):2459-75. doi: 10.1002/pmic.201000443. Epub 2011 May 18.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Fragment)
Q8TCZ8
Proteomic analysis of urinary exosomes from patients of early IgA nephropathy and thin basement membrane nephropathy.
Proteomics. 2011 Jun;11(12):2459-75. doi: 10.1002/pmic.201000443. Epub 2011 May 18.
ENOG4111MYC
347
/
0
/
347
mRNA for apolipoprotein E (apo E) (Fragment)
Q6LBZ1
Proteomic analysis of urinary exosomes from patients of early IgA nephropathy and thin basement membrane nephropathy.
Proteomics. 2011 Jun;11(12):2459-75. doi: 10.1002/pmic.201000443. Epub 2011 May 18.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic analysis of urinary exosomes from patients of early IgA nephropathy and thin basement membrane nephropathy.
Proteomics. 2011 Jun;11(12):2459-75. doi: 10.1002/pmic.201000443. Epub 2011 May 18.
ENOG4111MYC
347
/
0
/
347
mRNA for apolipoprotein E (apo E) (Fragment)
Q6LBZ1
Proteomic analysis of urinary exosomes from patients of early IgA nephropathy and thin basement membrane nephropathy.
Proteomics. 2011 Jun;11(12):2459-75. doi: 10.1002/pmic.201000443. Epub 2011 May 18.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic analysis of microvesicles derived from human colorectal cancer ascites.
Proteomics. 2011 Jul;11(13):2745-51. doi: 10.1002/pmic.201100022. Epub 2011 Jun 1.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E
Q6PAH0
Proteomics of microparticles after experimental pulmonary embolism.
Thromb Res. 2012 Jul;130(1):122-8. doi: 10.1016/j.thromres.2011.09.016. Epub 2011 Oct 19.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E
Q6PAH0
Proteomics of microparticles after experimental pulmonary embolism.
Thromb Res. 2012 Jul;130(1):122-8. doi: 10.1016/j.thromres.2011.09.016. Epub 2011 Oct 19.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P08226
Exosomes from Plasmodium yoelii-infected reticulocytes protect mice from lethal infections.
PLoS One. 2011;6(10):e26588. doi: 10.1371/journal.pone.0026588. Epub 2011 Oct 26.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic analysis of urine exosomes by multidimensional protein identification technology (MudPIT).
Proteomics. 2012 Jan;12(2):329-38. doi: 10.1002/pmic.201100477. Epub 2011 Dec 16.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
Q03247
Bovine milk exosome proteome.
J Proteomics. 2012 Feb 16;75(5):1486-92. doi: 10.1016/j.jprot.2011.11.017. Epub 2011 Nov 23.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
The protein interaction network of extracellular vesicles derived from human colorectal cancer cells.
J Proteome Res. 2012 Feb 3;11(2):1144-51. doi: 10.1021/pr200842h. Epub 2012 Jan 9.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Quantitative proteome profiling of normal human circulating microparticles.
J Proteome Res. 2012 Apr 6;11(4):2154-63. doi: 10.1021/pr200901p. Epub 2012 Mar 1.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic analysis of microvesicles from plasma of healthy donors reveals high individual variability.
J Proteomics. 2012 Jun 27;75(12):3574-84. doi: 10.1016/j.jprot.2012.03.054. Epub 2012 Apr 10.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET.
Nat Med. 2012 Jun;18(6):883-91. doi: 10.1038/nm.2753.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic analysis of microvesicles from plasma of healthy donors reveals high individual variability.
J Proteomics. 2012 Jun 27;75(12):3574-84. doi: 10.1016/j.jprot.2012.03.054. Epub 2012 Apr 10.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic analysis of microvesicles from plasma of healthy donors reveals high individual variability.
J Proteomics. 2012 Jun 27;75(12):3574-84. doi: 10.1016/j.jprot.2012.03.054. Epub 2012 Apr 10.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Biochemical and biologic characterization of exosomes and microvesicles as facilitators of HIV-1 infection in macrophages.
J Immunol. 2012 Jul 15;189(2):744-54. doi: 10.4049/jimmunol.1102244. Epub 2012 Jun 18.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Biochemical and physical characterisation of urinary nanovesicles following CHAPS treatment.
PLoS One. 2012;7(7):e37279. doi: 10.1371/journal.pone.0037279. Epub 2012 Jul 12.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Biochemical and physical characterisation of urinary nanovesicles following CHAPS treatment.
PLoS One. 2012;7(7):e37279. doi: 10.1371/journal.pone.0037279. Epub 2012 Jul 12.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteolytic Potential of the MSC Exosome Proteome: Implications for an Exosome-Mediated Delivery of Therapeutic Proteasome.
Int J Proteomics. 2012;2012:971907. doi: 10.1155/2012/971907. Epub 2012 Jul 18.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
In-depth analysis of the secretome identifies three major independent secretory pathways in differentiating human myoblasts.
J Proteomics. 2012 Dec 21;77:344-56. doi: 10.1016/j.jprot.2012.09.008. Epub 2012 Sep 20.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
In-depth analysis of the secretome identifies three major independent secretory pathways in differentiating human myoblasts.
J Proteomics. 2012 Dec 21;77:344-56. doi: 10.1016/j.jprot.2012.09.008. Epub 2012 Sep 20.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Cause or effect of arteriogenesis: compositional alterations of microparticles from CAD patients undergoing external counterpulsation therapy.
PLoS One. 2012;7(10):e46822. doi: 10.1371/journal.pone.0046822. Epub 2012 Oct 8.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Comparative and targeted proteomic analyses of urinary microparticles from bladder cancer and hernia patients.
J Proteome Res. 2012 Dec 7;11(12):5611-29. doi: 10.1021/pr3008732. Epub 2012 Oct 31.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Characterization and proteomic analysis of ovarian cancer-derived exosomes.
J Proteomics. 2013 Jan 16;80C:171-182. doi: 10.1016/j.jprot.2012.12.029.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Characterization and proteomic analysis of ovarian cancer-derived exosomes.
J Proteomics. 2013 Jan 16;80C:171-182. doi: 10.1016/j.jprot.2012.12.029.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02650
Urinary exosomes and diabetic nephropathy: a proteomic approach.
Mol Biosyst. 2013 Jun;9(6):1139-46. doi: 10.1039/c2mb25396h.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02650
Urinary exosomes and diabetic nephropathy: a proteomic approach.
Mol Biosyst. 2013 Jun;9(6):1139-46. doi: 10.1039/c2mb25396h.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic analysis of podocyte exosome-enriched fraction from normal human urine.
J Proteomics. 2013 Apr 26;82:193-229. doi: 10.1016/j.jprot.2013.01.012. Epub 2013 Jan 30.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
Q03247
Bovine milk proteome: quantitative changes in normal milk exosomes, milk fat globule membranes and whey proteomes resulting from Staphylococcus aureus mastitis.
J Proteomics. 2013 Apr 26;82:141-54. doi: 10.1016/j.jprot.2013.02.013. Epub 2013 Feb 28.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine.
Proteomics. 2013 May;13(10-11):1667-71. doi: 10.1002/pmic.201200561. Epub 2013 Apr 23.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine.
Proteomics. 2013 May;13(10-11):1667-71. doi: 10.1002/pmic.201200561. Epub 2013 Apr 23.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components.
Proteomics. 2013 May;13(10-11):1672-86. doi: 10.1002/pmic.201200562.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components.
Proteomics. 2013 May;13(10-11):1672-86. doi: 10.1002/pmic.201200562.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Identification and characterization of proteins isolated from microvesicles derived from human lung cancer pleural effusions.
Proteomics. 2013 Jul;13(14):2125-34. doi: 10.1002/pmic.201200323.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Heterogeneity in neutrophil microparticles reveals distinct proteome and functional properties.
Mol Cell Proteomics. 2013 Aug;12(8):2205-19. doi: 10.1074/mcp.M113.028589. Epub 2013 May 8.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Malaria-infected erythrocyte-derived microvesicles mediate cellular communication within the parasite population and with the host immune system.
Cell Host Microbe. 2013 May 15;13(5):521-34. doi: 10.1016/j.chom.2013.04.009.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Modulation of B-cell exosome proteins by gamma herpesvirus infection.
Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):E2925-33. doi: 10.1073/pnas.1303906110. Epub 2013 Jul 1.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Characterization of human thymic exosomes.
PLoS One. 2013 Jul 2;8(7):e67554. doi: 10.1371/journal.pone.0067554. Print 2013.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Exosomal signaling during hypoxia mediates microvascular endothelial cell migration and vasculogenesis.
PLoS One. 2013 Jul 8;8(7):e68451. doi: 10.1371/journal.pone.0068451. Print 2013.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
LRRK2 secretion in exosomes is regulated by 14-3-3.
Hum Mol Genet. 2013 Dec 15;22(24):4988-5000. doi: 10.1093/hmg/ddt346. Epub 2013 Jul 25.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Cellular stress conditions are reflected in the protein and RNA content of endothelial cell-derived exosomes.
J Extracell Vesicles. 2012 Apr 16;1. doi: 10.3402/jev.v1i0.18396. eCollection 2012.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteome profiling of neuroblastoma-derived exosomes reveal the expression of proteins potentially involved in tumor progression.
PLoS One. 2013 Sep 19;8(9):e75054. doi: 10.1371/journal.pone.0075054. eCollection 2013.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma.
Proteomics. 2013 Nov;13(22):3354-64. doi: 10.1002/pmic.201300282. Epub 2013 Oct 18.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P08226
Exosomes from myeloid-derived suppressor cells carry biologically active proteins.
J Proteome Res. 2014 Feb 7;13(2):836-43. doi: 10.1021/pr400879c. Epub 2013 Dec 13.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Exosomal ITGA3 interferes with non-cancerous prostate cell functions and is increased in urine exosomes of metastatic prostate cancer patients.
J Extracell Vesicles. 2013 Dec 23;2. doi: 10.3402/jev.v2i0.22097. eCollection 2013.
ENOG4111MYC
347
/
0
/
347
cDNA FLJ26517 fis, clone KDN07769
Q6ZP45
Exosomal ITGA3 interferes with non-cancerous prostate cell functions and is increased in urine exosomes of metastatic prostate cancer patients.
J Extracell Vesicles. 2013 Dec 23;2. doi: 10.3402/jev.v2i0.22097. eCollection 2013.
ENOG4111MYC
347
/
0
/
347
mRNA for apolipoprotein E (apo E) (Fragment)
Q6LBZ1
Exosomal ITGA3 interferes with non-cancerous prostate cell functions and is increased in urine exosomes of metastatic prostate cancer patients.
J Extracell Vesicles. 2013 Dec 23;2. doi: 10.3402/jev.v2i0.22097. eCollection 2013.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors.
Proteomics. 2014 Mar;14(6):699-712. doi: 10.1002/pmic.201300452. Epub 2014 Feb 16.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors.
Proteomics. 2014 Mar;14(6):699-712. doi: 10.1002/pmic.201300452. Epub 2014 Feb 16.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors.
Proteomics. 2014 Mar;14(6):699-712. doi: 10.1002/pmic.201300452. Epub 2014 Feb 16.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Exosomal proteins in the aqueous humor as novel biomarkers in patients with neovascular age-related macular degeneration.
J Proteome Res. 2014 Feb 7;13(2):581-95. doi: 10.1021/pr400751k. Epub 2014 Jan 16.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
In-depth proteomic analyses of ovarian cancer cell line exosomes reveals differential enrichment of functional categories compared to the NCI 60 proteome.
Biochem Biophys Res Commun. 2014 Mar 21;445(4):694-701. doi: 10.1016/j.bbrc.2013.12.070. Epub 2014 Jan 14.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Plasma biomarker discovery in preeclampsia using a novel differential isolation technology for circulating extracellular vesicles.
Am J Obstet Gynecol. 2014 Mar 18. pii: S0002-9378(14)00248-8. doi: 10.1016/j.ajog.2014.03.038.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Plasma biomarker discovery in preeclampsia using a novel differential isolation technology for circulating extracellular vesicles.
Am J Obstet Gynecol. 2014 Mar 18. pii: S0002-9378(14)00248-8. doi: 10.1016/j.ajog.2014.03.038.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Plasma biomarker discovery in preeclampsia using a novel differential isolation technology for circulating extracellular vesicles.
Am J Obstet Gynecol. 2014 Mar 18. pii: S0002-9378(14)00248-8. doi: 10.1016/j.ajog.2014.03.038.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Quantitative proteomics of extracellular vesicles released from human monocyte-derived macrophages upon beta-glucan stimulation.
J Proteome Res. 2014 May 2;13(5):2468-77. doi: 10.1021/pr4012552. Epub 2014 Apr 16.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Human urinary exosomes as innate immune effectors.
J Am Soc Nephrol. 2014 Sep;25(9):2017-27. doi: 10.1681/ASN.2013101066. Epub 2014 Apr 3.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02650
Quantitative proteomic analysis of hepatocyte-secreted extracellular vesicles reveals candidate markers for liver toxicity.
J Proteomics. 2014 May 30;103:227-40. doi: 10.1016/j.jprot.2014.04.008. Epub 2014 Apr 18.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02650
Quantitative proteomic analysis of hepatocyte-secreted extracellular vesicles reveals candidate markers for liver toxicity.
J Proteomics. 2014 May 30;103:227-40. doi: 10.1016/j.jprot.2014.04.008. Epub 2014 Apr 18.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Discovery of prognostic biomarker candidates of lacunar infarction by quantitative proteomics of microvesicles enriched plasma.
PLoS One. 2014 Apr 21;9(4):e94663. doi: 10.1371/journal.pone.0094663. eCollection 2014.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Discovery of prognostic biomarker candidates of lacunar infarction by quantitative proteomics of microvesicles enriched plasma.
PLoS One. 2014 Apr 21;9(4):e94663. doi: 10.1371/journal.pone.0094663. eCollection 2014.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Discovery of prognostic biomarker candidates of lacunar infarction by quantitative proteomics of microvesicles enriched plasma.
PLoS One. 2014 Apr 21;9(4):e94663. doi: 10.1371/journal.pone.0094663. eCollection 2014.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Discovery of prognostic biomarker candidates of lacunar infarction by quantitative proteomics of microvesicles enriched plasma.
PLoS One. 2014 Apr 21;9(4):e94663. doi: 10.1371/journal.pone.0094663. eCollection 2014.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset.
J Proteomics. 2014 Jun 25;106:191-204. doi: 10.1016/j.jprot.2014.04.028. Epub 2014 Apr 24.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P18649
Characterization of the canine urinary proteome.
Vet Clin Pathol. 2014 Jun;43(2):193-205. doi: 10.1111/vcp.12147. Epub 2014 Apr 28.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Human T-lymphotropic Virus Type 1-infected Cells Secrete Exosomes That Contain Tax Protein.
J Biol Chem. 2014 Aug 8;289(32):22284-305. doi: 10.1074/jbc.M114.549659. Epub 2014 Jun 17.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Extravillous trophoblast cells-derived exosomes promote vascular smooth muscle cell migration.
Front Pharmacol. 2014 Aug 11;5:175. doi: 10.3389/fphar.2014.00175. eCollection 2014.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Extravillous trophoblast cells-derived exosomes promote vascular smooth muscle cell migration.
Front Pharmacol. 2014 Aug 11;5:175. doi: 10.3389/fphar.2014.00175. eCollection 2014.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Antibody-coupled monolithic silica microtips for highthroughput molecular profiling of circulating exosomes.
Sci Rep. 2014 Aug 29;4:6232. doi: 10.1038/srep06232.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Quantitative Proteomic Analysis of Exosome Protein Content Changes Induced by Hepatitis B Virus in Huh-7 Cells Using SILAC Labeling and LC-MS/MS.
J Proteome Res. 2014 Oct 8.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Quantitative Proteomic Analysis of Exosome Protein Content Changes Induced by Hepatitis B Virus in Huh-7 Cells Using SILAC Labeling and LC-MS/MS.
J Proteome Res. 2014 Oct 8.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Quantitative Proteomic Analysis of Exosome Protein Content Changes Induced by Hepatitis B Virus in Huh-7 Cells Using SILAC Labeling and LC-MS/MS.
J Proteome Res. 2014 Oct 8.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Quantitative Proteomic Analysis of Exosome Protein Content Changes Induced by Hepatitis B Virus in Huh-7 Cells Using SILAC Labeling and LC-MS/MS.
J Proteome Res. 2014 Oct 8.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Lipidomic and proteomic characterization of platelet extracellular vesicle subfractions from senescent platelets.
Transfusion. 2014 Oct 21. doi: 10.1111/trf.12874.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
Lipidomic and proteomic characterization of platelet extracellular vesicle subfractions from senescent platelets.
Transfusion. 2014 Oct 21. doi: 10.1111/trf.12874.
ENOG4111MYC
347
/
0
/
347
Apolipoprotein E (Apo-E)
P02649
A New Workflow for Proteomic Analysis of Urinary Exosomes and Assessment in Cystinuria Patients.
J Proteome Res. 2014 Nov 12.
ENOG4111MYC
347
/
0
/
347
[1]
[2]
[3]
[4]